Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
June 30, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code:600276 Stock abbreviation: Hengrui Pharma No.: Lin 2025-097

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company"), received a notice from the National Medical Products Administration (the "NMPA"). The NMPA approves an addition of a new indication of the Company's self-developed Class 1 innovative drug, Ivarmacitinib Sulfate Tablets (SHR0302). It is indicated for the treatment of adult patients with severe alopecia areata. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Common name of drug: Ivarmacitinib Sulfate Tablets

Dosage Form: Tablet

Specification: 4mg

Registered Category: Class 1 chemical drug

Application Number: CXHS2400089

Prescription/Non-prescription Drug: Prescription Drug

Approved indication: The treatment of adult patients with severe alopecia areata

II. Other Information of the Drug

Alopecia areata (AA) is a chronic, immune-mediated, inflammatory, non-scarring form of hair loss that can occur at any age and negatively affects

patients' mental health and quality of life.[1] Epidemiological data indicate that the lifetime prevalence of alopecia areata in the global population is as high as 2%.[2] The prevalence is even higher in Asian countries/regions. In 2021, approximately 3.49 million patients in China were affected by alopecia areata, which the burden of the disease should not be neglected.[3] Currently, there are still many unmet needs among patients with alopecia areata. The course and prognosis of alopecia areata vary from person to person. Most mild cases recover naturally or after treatment. However, severe alopecia areata is difficult to cure. Long-term use of glucocorticoids and immunosuppressants not only results in significant side effects, but also presents treatment challenges in the form of diminishing efficacy, treatment resistance, and a high relapse rate after discontinuation, etc.[1,4,5] At the same time, alopecia areata seriously harms the patients' work, daily life, and mental health, with a particularly high prevalence of depression and anxiety among those with severe alopecia areata.[6,7] Therefore, there is an urgent need for innovative treatment regimens that can effectively promote and durably maintain hair regrowth in patients with alopecia areata, which are also safe for long-term use and convenient to administer.

Ivarmacitinib Sulfate Tablets is a highly selective JAK1 inhibitor that exerts anti-inflammatory and immunosuppressive biological effects by inhibiting JAK1 signaling pathways. Ivarmacitinib Sulfate Tablets has been approved for three indications in China, namely: adults with active ankylosing spondylitis who have shown inadequate efficacy or intolerance to one or more TNF inhibitors; adults with moderate-to-severe active rheumatoid arthritis who have shown inadequate efficacy or intolerance to one or more TNF inhibitors; adults with moderate-to-severe atopic dermatitis who showed inadequate efficacy or intolerance to topical treatment or other systemic therapies. At present, oral drugs with similar targets for alopecia areata have been approved for marketing worldwide, including Pfizer's Ritlecitinib capsules（LITFULO®）, Eli Lilly's Baricitinib tablets（OLUMIANT®）and Sun Pharmaceutical Industries' Deuruxolitinib tablets（LEQSELVI™）, etc. However, no JAK1 inhibitors developed by Chinese domestic companies have been approved for marketing. According to the EvaluatePharma database, the combined global sales of

Ritlecitinib capsules and Baricitinib tablets in 2024 amounted to approximately USD 1.047 billion. To date, the total accumulated R&D investment in the Ivarmacitinib Sulfate Tablets project is approximately RMB 1,091 million.

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

June 30, 2025

[1]. Hair Group, Dermatology Division, Chinese Medical Association. Journal of Clinical Dermatology. 2020;49(2):69-72.
[2]. Lee HH,et al. J Am Acad Dermatol. 2020;82(3):675-682.
[3]. Li X, et al. Chin Med J (Engl). 2025 Feb 5;138(3):318-324.
[4]. Zhang XQ. Diagnosis and Therapy Journal of Dermato-Venereology, 2022,29(02):93-100.
[5]. Hammerschmidt M, et al.An Bras Dermatol 2014; 89:729–34.
[6]. Liu LY, et al. J Am Acad Dermatol. 2016 Oct;75(4):806-812.e3.
[7]. Lintzeri DA, et al. J Dtsch Dermatol Ges. 2022;20(1)59-90.